July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Tom Powles: Debate about activity of neoadjuvant vs adjuvant vs both is ongoing
May 23, 2024, 13:33

Tom Powles: Debate about activity of neoadjuvant vs adjuvant vs both is ongoing

Tom Powles, Director of Barts Cancer Center, shared a post on X:

“Neoadjuvant chemo/nivolumab with adjuvant nivolumab show high DFS (HR 0.58) and high pCR in NSCLC.

23% and 35% didn’t have surgery/adjuvant nivolumab respectively.

Debate about activity of neoadjuvant vs adjuvant vs both is ongoing. No OS. Similar Bladder cancer trials (durvalumab/nivolumab/pembrolizumab) awaited.”

Source: Tom Powles/X